| __timestamp | Agios Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 24419536 |
| Thursday, January 1, 2015 | 35992000 | 34718089 |
| Friday, January 1, 2016 | 50714000 | 40998209 |
| Sunday, January 1, 2017 | 71124000 | 32022880 |
| Monday, January 1, 2018 | 114145000 | 19110051 |
| Tuesday, January 1, 2019 | 132034000 | 26556257 |
| Wednesday, January 1, 2020 | 149070000 | 52275890 |
| Friday, January 1, 2021 | 121445000 | 80981000 |
| Saturday, January 1, 2022 | 121673000 | 124431000 |
| Sunday, January 1, 2023 | 119903000 | 90932000 |
| Monday, January 1, 2024 | 156784000 | 98761000 |
Data in motion
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Arrowhead Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Agios Pharmaceuticals saw a significant increase in SG&A expenses, peaking in 2020 with a 680% rise from 2014. Meanwhile, Arrowhead Pharmaceuticals experienced a more moderate growth, with expenses increasing by approximately 410% over the same period.
Interestingly, in 2022, Arrowhead's SG&A expenses surpassed Agios for the first time, marking a pivotal shift in their financial strategies. This trend continued into 2023, highlighting Arrowhead's aggressive expansion and investment in administrative capabilities. However, data for Agios in 2024 is missing, leaving room for speculation on their future financial trajectory. This comparison underscores the dynamic nature of financial management in the biotech industry.
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.